What is Core Technology Solutions?
Core Technology Solutions operates as an integrated research, development, and manufacturing entity specializing in transdermal drug delivery systems. The company distinguishes itself through a comprehensive portfolio of proprietary and generic controlled-release patch products. By mastering both membrane-controlled and matrix-controlled formulations, the firm provides end-to-end services that span from initial drug development to large-scale commercial manufacturing. This vertical integration allows the company to maintain stringent quality control while optimizing the delivery of active pharmaceutical ingredients, positioning it as a critical partner for pharmaceutical developers seeking reliable, scalable transdermal solutions.
How much funding has Core Technology Solutions raised?
Core Technology Solutions has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Core Technology Solutions
PPP
Public-Private Partnership
What's next for Core Technology Solutions?
With this late-stage funding secured, Core Technology Solutions is poised to scale its manufacturing capabilities and expand its footprint in the global pharmaceutical market. The strategic focus will likely shift toward optimizing production efficiencies and potentially diversifying its pipeline of controlled-release formulations. By leveraging its established infrastructure, the company is expected to enhance its competitive advantage in the transdermal space, focusing on high-barrier-to-entry products that require specialized technical proficiency. Future growth will be driven by the successful commercialization of its current development projects and the continued refinement of its proprietary delivery technologies, ensuring long-term value creation for stakeholders in the life sciences sector.
See full Core Technology Solutions company page
